Yartemlea® (Narsoplimab-wuug) - CAM 971HB

Background

FDA-Approved Indication: Yartemlea is a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). It is the first FDA-approved therapy specifically indicated for TA-TMA.

Policy

Initial Authorization Criteria

Yartemlea may be considered medically necessary when all of the following criteria are met:

1. Diagnosis of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)

2. Patient is 2 years of age or older

3. Patient has undergone allogeneic or autologous hematopoietic stem cell transplantation

4. Diagnosis of TA-TMA is supported by clinical and laboratory evidence, including all of the following:

  • Microangiopathic hemolytic anemia
  • Thrombocytopenia
  • Elevated lactate dehydrogenase (LDH)
  • Presence of schistocytes on peripheral blood smear (if available)
  • No alternative explanation for thrombotic microangiopathy

5. Documentation of one or more TA-TMA-related clinical manifestations:

  • Renal dysfunction
  • Hypertension
  • Neurologic dysfunction
  • Gastrointestinal involvement
  • Transfusion dependence
  • Other evidence of end-organ injury attributable to TA-TMA

6. Prescribed by or in consultation with one of the following:

  • Hematologist
  • Bone marrow transplant specialist
  • Pediatric hematologist/oncologist
  • Physician experienced in the management of TA-TMA

7. Dose does not exceed FDA-labeled dosing:

  • ≥ 50 kg: 370 mg IV once weekly
  • < 50 kg: 4 mg/kg IV once weekly

Frequency may be increased to twice weekly for inadequate improvement in TA-TMA signs and symptoms.

Authorization Duration: 3 months

Reauthorization Criteria

Yartemlea may be reauthorized when all of the following criteria are met:

1. Documentation of positive clinical response to therapy examples include one or more of the following:

  • Improvement in platelet count
  • Reduction in LDH levels
  • Reduced transfusion requirements
  • Improvement in renal function
  • Improvement in organ dysfunction attributable to TA-TMA
  • Resolution or improvement of microangiopathic hemolysis
  • Physician-documented improvement in TA-TMA

2. Continued evidence that TA-TMA remains an active treatment concern and ongoing therapy is clinically warranted

3. Prescribed by or in consultation with a hematologist, transplant physician, or specialist experienced in TA-TMA management

Authorization Duration: 6 months

References

  1. YARTEMLEA (narsoplimab-wuug) Prescribing Information. Omeros Corporation. Revised December 2025. turn14search7
  2. U.S. Food and Drug Administration. FDA Approves First rug to Treat Serious Complication of Stem Cell Transplant. January 2026. turn14search8
  3. U.S. Food and Drug Administration. Drug Trials Snapsho: YARTEMLEA. 2025. turn14search12
  4. Omeros Corporation. YARTEMLEA Healthcare Professional Information. turn14search10
  5. Jodele S, Dandoy CE, Myers KC, et al. Transplant-associated thrombotic microangiopthy: diagnosis, risk stratification, and management. Current peer-reviewed literature.
  6. American Society for Transplantation and Cellular Therapy (ASTCT). Guidance regarding diagnosis and management of TA-TMA.

Coding Section

Code

Number

Description

ICD-10

M31.11

 

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). Transplant-associated thrombotic microangiopathy (TA-TMA)

 

T86.5

Complications of stem cell transplant Complications from stem cells from peripheral blood

HCPCS

J1289

Injection, narsoplimab-wuug, 1 mg

 

J3590

Unclassified biologics

 

J3490

Unclassified drugs

CPT

96365

Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

 

96413

Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2026 Forward

10/01/2026

New Policy

Complementary Content
${loading}